The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme

Eur Respir J. 2022 Aug 10;60(2):2102760. doi: 10.1183/13993003.02760-2021. Print 2022 Aug.

Abstract

Relievers account for the majority of inhaler use and associated GHG emissions. Implementing treatment guidelines can reduce the unmet need in respiratory care by improving disease control and reducing reliever overuse and the overall carbon footprint. https://bit.ly/3zh3c2B

Publication types

  • Letter
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Canada
  • Carbon Dioxide* / analysis
  • Carbon Footprint*
  • Europe
  • Humans

Substances

  • Carbon Dioxide